EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Champions Oncology's enterprise value is $103.07 Mil.
Champions Oncology's Revenue for the trailing twelve months (TTM) ended in Jan. 2025 was $58.59 Mil. Therefore, Champions Oncology's EV-to-Revenue for today is 1.76.
The historical rank and industry rank for Champions Oncology's EV-to-Revenue or its related term are showing as below:
CSBR'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0.84 Med: 2.45 Max: 10.25
Current: 1.76
During the past 13 years, the highest EV-to-Revenue of Champions Oncology was 10.25. The lowest was 0.84. And the median was 2.45.
CSBR's EV-to-Revenue is ranked better than 79.92% of 996
companies
in the Biotechnology industry
Industry Median: 7.685
vs CSBR: 1.76
The historical data trend for Champions Oncology's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Champions Oncology's EV-to-Revenue
For the Biotechnology subindustry, Champions Oncology's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Champions Oncology's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Champions Oncology's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Champions Oncology's EV-to-Revenue falls into.
Champions Oncology's current Enterprise Value is $103.07 Mil.
Champions Oncology's Revenue for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $58.59 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Champions Oncology (NAS:CSBR) EV-to-Revenue Explanation
Champions Oncology's share price for today is $7.62.
Champions Oncology's Revenue per Share for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.18.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Champions Oncology EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Champions Oncology's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CSBR has been successfully added to your 